Blood cancers, Lymphoma
Open
Phase 2/3
This trial is looking at zilovertamab vedotin with a for people with diffuse large B cell lymphoma.
You pronounce zilovertamab vedotin as zi-lov-er-ta-mab ve-dot-in.
It is open to people whose diffuse large B cell lymphoma (DLBCL) has come back after treatment (relapsed) or got worse during treatment (refractory).
Recruitment start: 4 October 2023
Recruitment end: 24 September 2027
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Satyen Gohil
Merck Sharp & Dohme Ltd
Last reviewed: 24 August 2025
CRUK internal database number: 19581
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
